QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
Free Trial
ASX:RAD

Radiopharm Theranostics (RAD) Stock Price, News & Analysis

→ I’m officially sounding the alarm. (From Altimetry) (Ad)
Free RAD Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
RAD stock logo

About Radiopharm Theranostics Stock (ASX:RAD)

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.

RAD Stock News Headlines

April 10, 2024 | msn.com
Lisata wins FDA orphan drug status for bone cancer candidate
April 9, 2024 | msn.com
Radiopharmaceutical emerges as the hottest space in biotech; here’s what it means for Clarity Pharma
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 16, 2024 | morningstar.com
Radiopharm Theranostics Ltd Ordinary Shares
February 25, 2024 | msn.com
Radiopharmaceutical market expected to reach ~$14B by 2032
February 13, 2024 | uk.finance.yahoo.com
Radiopharm Theranostics Limited (RDPTF)
February 5, 2024 | au.investing.com
Radiopharm Theranostics' novel monoclonal antibody shows promise in cancer treatment
January 26, 2024 | au.investing.com
Radiopharm Theranostics completes entitlement offer shortfall for $1.7 million
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
January 20, 2024 | morningstar.com
Radiopharm Theranostics Ltd Ordinary Shares RAD
December 27, 2023 | au.investing.com
Radiopharm Theranostics to open second Australian site for lung cancer trial
December 22, 2023 | au.investing.com
Radiopharm Theranostics launching Phase 1 lung cancer trials in January
November 20, 2023 | au.investing.com
Radiopharm Theranostics' $4.85 million R&D refund will support development of radiopharmaceutical products
October 30, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics launches $10 million entitlement offer to fund clinical trials
October 16, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics receives FDA greenlight to start Phase 1 imaging trial of RAD 301
October 9, 2023 | finance.yahoo.com
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
October 9, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics secures approval for Phase 1 PDL1-nanobody non-small cell lung cancer study
September 1, 2023 | finance.yahoo.com
Radiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)
August 24, 2023 | finance.yahoo.com
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
August 24, 2023 | proactiveinvestors.com
Radiopharm Theranostics expands TerThera supply agreement for prostate cancer treatment trial
July 24, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics appoints experienced radiopharmaceutical developer as VP Medical and Corporate Affairs
July 23, 2023 | finance.yahoo.com
Theradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%
July 19, 2023 | finance.yahoo.com
Is Radiopharm Theranostics (ASX:RAD) In A Good Position To Invest In Growth?
June 23, 2023 | marketwatch.com
Radiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac Applications
June 9, 2023 | finance.yahoo.com
Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023
June 6, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics maintains A$0.70 valuation from Diamond Equity Research
May 31, 2023 | proactiveinvestors.com.au
Radiopharm welcomes positive guidance from FDA to advance Pivalate
See More Headlines
Receive RAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:RAD
CUSIP
N/A
CIK
N/A
Web
www.riteaid.com
Phone
17177612633
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-46,820,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-107.05%
Return on Assets
-30.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.50
Quick Ratio
3.43

Sales & Book Value

Annual Sales
$6.01 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.06 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
445,130,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.96
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)
    B.A (UNSW), FAICD, Founder & Executive Chairman
    Comp: $271.45k
  • Mr. Riccardo Canevari
    MD, CEO & Director
  • Mr. Vittorio Puppo M.D.
    Chief Operating Officer
  • Prof. David Mozley
    Chief Medical Officer & Scientific Advisory Board Chair
  • Dr. Thomas H. Tulip Ph.D. (Age 71)
    Chief Business Officer
    Comp: $504.74k
  • Mr. Phillip Hains
    CFO & Company Secretary
  • Dr. Scot L. Harper Ph.D. (Age 67)
    Senior Vice President of Clinical Operations
  • Mr. Bill Regan
    Senior Vice President of Regulatory Strategy
  • Dr. Rama Abu Shmeis
    Senior VP of Chemistry, Manufacturing & Controls
  • Mr. Nathan Jong C.A.
    Company Secretary

Key Competitors

View All Competitors

Insiders


This page (ASX:RAD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research